Company Description
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients.
Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.
The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems.
In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs.
The company was founded in 2006 and is headquartered in Rochester, Michigan.
| Country | United States |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 109 |
| CEO | William J. Febbo |
Contact Details
Address: 260 Charles Street, Suite 302 Waltham, Massachusetts 02453 United States | |
| Phone | 248-651-6558 |
| Website | optimizerx.com |
Stock Details
| Ticker Symbol | OPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001448431 |
| CUSIP Number | 68401U204 |
| ISIN Number | US68401U2042 |
| Employer ID | 26-1265381 |
| SIC Code | 7389 |
Key Executives
| Name | Position |
|---|---|
| William J. Febbo | Chief Executive Officer and Director |
| Stephen L. Silvestro | President |
| Edward Stelmakh C.M.A., M.B.A. | Chief Financial Officer and Chief Operating Officer |
| Andrew Jacob D'Silva | Senior Vice President of Corporate Finance |
| Todd Inman | Chief Technology Officer |
| Marion K Odence-Ford | General Counsel and Chief Compliance Officer |
| Maira Alejandra | Media Relations Manager |
| Sheryl Kearney | Human Resources Manager |
| Terence J. Hamilton | Senior Vice President of Pharma |
| Dr. Doug Besch | Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 10-K | Annual Report |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 28, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 9, 2024 | 144 | Filing |
| Jan 5, 2024 | 8-K/A | [Amend] Current report |